Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 6/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.35 |
| ▸ | PRKDC | P78527 | 4/20 | 0.35 |
| ▸ | MTOR | P42345 | 2/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | WEE1 | P30291 | 2/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | LYN | P07948 | 3/20 | 0.33 |
| ▸ | SRC | P12931 | 3/20 | 0.33 |
| ▸ | CDK4 | P11802 | 1/20 | 0.33 |
| ▸ | CCND1 | P24385 | 1/20 | 0.33 |
| ▸ | CCND2 | P30279 | 1/20 | 0.33 |
| ▸ | CCND3 | P30281 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10201949 | 1.00 | MKNK2 (0.35) | MKNK2BTKPIK3CAPRKDCMTOR | |
| SCHEMBL10201508 | 0.88 | MKNK2 (0.33) | MKNK2BTKPIK3CAPRKDCMTOR | |
| SCHEMBL610188 | 0.85 | BTK (0.42) | BTKPIK3CAPRKDCMTORCDK4 | |
| SCHEMBL610189 | 0.85 | BTK (0.42) | BTKPIK3CAPRKDCMTORCDK4 | |
| SCHEMBL610952 | 0.81 | WEE1 (0.51) | BTKWEE1CDK4CCND1CCND3 | |
| SCHEMBL610863 | 0.77 | CDK6 (0.41) | BTKCDK4CCND1CCND3 | |
| SCHEMBL607847 | 0.77 | CDK6 (0.41) | BTKCDK4CCND1CCND3 | |
| SCHEMBL611366 | 0.77 | CDK6 (0.41) | BTKCDK4CCND1CCND3 | |
| SCHEMBL610905 | 0.77 | SYK (0.43) | BTKWEE1CDK4CCND1CCND3 | |
| SCHEMBL10256584 | 0.77 | CCND3 (0.48) | CDK4CCND1CCND2CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940741-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2015-01-27 | — | — | US | disclosed |
| EP-2603500-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2014-11-19 | — | — | EP | disclosed |
| US-20130178461-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-8481540-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120040949-A1 | Inhibitors of Bruton's Tyrosine Kinase | BERTHEL STEVEN JOSEPH (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040949-A1 | Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LYN | MKNK2 398/4885BTK 1/4885PIK3CA 177/4885 |
| US-20130178461-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | MKNK2 398/4885BTK 1/4885PIK3CA 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.